Cover Image
市場調查報告書

原發性骨髓纖維化 (PMF) 的主要8個國家市場預測

Primary Myelofibrosis (PMF) Forecast in 8 Major Markets 2016-2026

出版商 Black Swan Analysis 商品編碼 356342
出版日期 內容資訊 英文 40 Pages
訂單完成後即時交付
價格
Back to Top
原發性骨髓纖維化 (PMF) 的主要8個國家市場預測 Primary Myelofibrosis (PMF) Forecast in 8 Major Markets 2016-2026
出版日期: 2016年04月19日 內容資訊: 英文 40 Pages
簡介

本報告提供全球主要8個國家市場上原發性骨髓纖維化之罹患情形調查,提供您得病數的變化與預測,性別·症狀等各種類別的明細,並彙整疾病概要,危險因素,疾病診斷預後,主要的症狀和併發症等資料。

調查對象國家

  • 美國
  • 法國
  • 德國
  • 義大利
  • 西班牙
  • 英國
  • 巴西
  • 日本

目錄

  • 簡介
  • 病因
  • 危險因素和預防
  • 疾病診斷
  • 地區/各民族的差異
  • 疾病預後和臨床過程
  • 疾病相關的主要併發症/特徵
  • 患者數定量化的手法
  • PMF的患病人數
  • PMF患者的特徵
    • PMF的階段和評分
    • PMF患者的細胞數
    • PMF的相關症狀
    • PMF患者的JAK2變異
  • 簡稱
  • 相關出版物
  • 線上資料庫
  • 參考文獻
  • 附錄
目錄
Product Code: PYMF0010416

image1

Primary Myelofibrosis (PMF), also known as myelofibrosis, myeloid metaplasia or chronic idiopathic myelofibrosis, is part of the collection of diseases known as myeloproliferative neoplasms (MPNs). PMF is a chronic blood cancer that affects the haematopoietic system, causing progressive fibrosis of the bone marrow and impairs the ability of new blood cell production. Eventually, the bone marrow is unable to produce blood cells, and the spleen and liver take over the function causing abdominal swelling and discomfort.

This report provides the current prevalent population for PMF across 8 Major Markets (USA, France, Germany, Italy, Spain, UK, Brazil and Japan) split by gender and 5-year age cohort. Along with the current prevalence, the report also contains a disease overview of the risk factors, disease diagnosis and prognosis along with specific variations by geography and ethnicity.

Providing a value-added level of insight from the analysis team at Black Swan, several of the main symptoms and co-morbidities of PMF have been quantified and presented alongside the overall prevalence figures. These sub-populations within the main disease are also included at a country level across the 10-year forecast snapshot.

Main symptoms and co-morbidities for PMF include:

  • Portal hypertension
  • Thrombosis
  • Anaemia
  • Gout
  • Extramedullary haematopoiesis
  • Leukocytosis
  • Splenomegaly
  • Acute myeloid leukaemia

This report is built using data and information sourced from the proprietary Epiomic patient segmentation database. To generate accurate patient population estimates, the Epiomic database utilises a combination of several world class sources that deliver the most up to date information from patient registries, clinical trials and epidemiology studies. All of the sources used to generate the data and analysis have been identified in the report.

Reason to buy

  • Able to quantify patient populations in global PMF's market to target the development of future products, pricing strategies and launch plans.
  • Gain further insight into the prevalence of the subdivided types of PMF and identify patient segments with high potential.
  • Delivery of more accurate information for clinical trials in study sizing and realistic patient recruitment for various countries.
  • Provide a level of understanding on the impact from specific co-morbid conditions on PMF's prevalent population.
  • Identify sub-populations within PMF which require treatment.
  • Gain an understanding of the specific markets that have the largest number of PMF patients.

Coverage

BR, FR, DE, IT, JP, ES, UK, US

image2

Table of Contents

List of Tables and Figures

Introduction

Cause of the Disease

Risk Factors & Prevention

Diagnosis of the Disease

Variation by Geography/Ethnicity

Disease Prognosis & Clinical Course

Key Co-morbid Conditions/Features Associated with the Disease

Methodology for Quantification of Patient Numbers

Top-Line Prevalence for Primary Myelofibrosis

Features of PMF Patients

  • Staging and Scores of PMF
  • Cell Counts in PMF Patients
  • Associated Conditions of PMF
  • JAK2 Mutation in PMF Patients

Abbreviations used in the Report

Other Black Swan Analysis Publications

Black Swan Analysis Online Patient-Based Databases

Patient-Based Offering

Online Pricing Data and Platforms

References

Appendix

List of Tables

  • Prevalence of PMF, total (000s)
  • Prevalence of PMF, males (000s)
  • Prevalence of PMF, females (000s)
  • Dupriez score in PMF patients, total (000s)
  • Bone marrow staging in PMF patients, total (000s)
  • White blood cell count (x 109 /dL) in PMF patients, total (000s)
  • Platelet count (x 109 /dL) in PMF patients, total (000s)
  • Circulating blasts (%) in PMF patients, total (000s)
  • Hepatomegaly in PMF patients, total (000s)
  • Spleen size (cm) below the costal margin in PMF patients, total (000s)
  • Incidence of thrombosis, total (000s)
  • Thrombosis outcome in patients, total (000s)
  • Prevalence of JAK2-VG17F mutation, total (000s)
  • Abbreviations and Acronyms used in the report
  • USA Prevalence of PMF by 5-yr age cohort, males (000s)
  • USA Prevalence of PMF by 5-yr age cohort, females (000s)
  • France Prevalence of PMF by 5-yr age cohort, males (000s)
  • France Prevalence of PMF by 5-yr age cohort, females (000s)
  • Germany Prevalence of PMF by 5-yr age cohort, males (000s)
  • Germany Prevalence of PMF by 5-yr age cohort, females (000s)
  • Italy Prevalence of PMF by 5-yr age cohort, males (000s)
  • Italy Prevalence of PMF by 5-yr age cohort, females (000s)
  • Spain Prevalence of PMF by 5-yr age cohort, males (000s)
  • Spain Prevalence of PMF by 5-yr age cohort, females (000s)
  • United Kingdom Prevalence of PMF by 5-yr age cohort, males (000s)
  • United Kingdom Prevalence of PMF by 5-yr age cohort, females (000s)
  • Brazil Prevalence of PMF by 5-yr age cohort, males (000s)
  • Brazil Prevalence of PMF by 5-yr age cohort, females (000s)
  • Japan Prevalence of PMF by 5-yr age cohort, males (000s)
  • Japan Prevalence of PMF by 5-yr age cohort, females (000s)
Back to Top